Clinical Trials Logo

Clinical Trial Summary

This is a non interventional, multicenter clinical trial, in adult patients receiving Tecfidera per approved SmPC and routine clinical practice. The primary objective of this study is to evaluate the total societal costs to the healthcare system related to the use of Tecfidera in RRMS patients. The study will capture data in a simple matter that can be easily interpreted providing an advantage in a country where efforts in the market access arena are in their infancy. For the aforementioned reasons, the proposed study may prove quite valuable in supporting DMF as a cost-effective therapy, valuable not only for patients but for the public health care system as well, providing all the necessary information for the evaluation that need to be examined regarding the positive reimbursement list and future decisions.


Clinical Trial Description

The study will take place in Greece. Investigators will participate from a broad geographical distribution in order to ensure a proper representation from all areas of Greece. Investigator's decision to prescribe DMF (Tecfidera®) (according to the indication for treatment as defined in the summary of product characteristics, SmPC and the current clinical practice), should precede entry into the study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03101735
Study type Observational
Source Genesis Pharma CNS & Specialty
Contact
Status Completed
Phase
Start date September 23, 2016
Completion date April 23, 2020

See also
  Status Clinical Trial Phase
Completed NCT02907281 - Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis N/A
Completed NCT01051817 - POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler Phase 2